Back to top
more

ADMA Biologics Inc (ADMA)

(Delayed Data from NSDQ)

$2.04 USD

2.04
2,067,951

-0.05 (-2.39%)

Updated Mar 8, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (192 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards?

Ocugen (OCGN) will provide updates on its pipeline when it reports fourth-quarter 2020 results.

Kinjel Shah headshot

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?

Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

Adma Biologics (ADMA) Upgraded to Buy: Here's Why

Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?

Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.

Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?

On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

ADMA Biologics (ADMA) in Focus: Stock Moves 6.6% Higher

ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of 9.52% and 7.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?

On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

Analysts Estimate Adma Biologics (ADMA) to Report a Decline in Earnings: What to Look Out for

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 14th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Is the Options Market Predicting a Spike in ADMA Biologics (ADMA) Stock?

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

ADMA Biologics (ADMA) Surges: Stock Moves 8.6% Higher

ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Are Options Traders Betting on a Big Move in ADMA Stock?

Investors need to pay close attention to ADMA stock based on the movements in the options market lately.

Adma Biologics (ADMA) Reports Q2 Loss, Lags Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of -21.05% and -24.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in ADMA Stock?

Investors need to pay close attention to ADMA stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in ADMA Biologics (ADMA) Stock?

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Adma Biologics (ADMA) Reports Q1 Loss, Misses Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?